Escitalopram, but Not Its Major Metabolites, Exhibits Antiplatelet Activity in Humans

Abstract

Escitalopram, but not its metabolites, exhibited selective inhibition of human platelet properties. The direct antiplatelet effect of ESC requires further prospective or ex vivo testing to determine the possible clinical advantage of this finding.